MX2024003948A - Nuevos compuestos de sulfonilurea sustituidos como inhibidores de la actividad de interleucina-1. - Google Patents
Nuevos compuestos de sulfonilurea sustituidos como inhibidores de la actividad de interleucina-1.Info
- Publication number
- MX2024003948A MX2024003948A MX2024003948A MX2024003948A MX2024003948A MX 2024003948 A MX2024003948 A MX 2024003948A MX 2024003948 A MX2024003948 A MX 2024003948A MX 2024003948 A MX2024003948 A MX 2024003948A MX 2024003948 A MX2024003948 A MX 2024003948A
- Authority
- MX
- Mexico
- Prior art keywords
- interleukin
- inhibitors
- activity
- novel substituted
- sulfonylurea compounds
- Prior art date
Links
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 title abstract 2
- 102000000589 Interleukin-1 Human genes 0.000 title 1
- 108010002352 Interleukin-1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021121548 | 2021-09-29 | ||
| PCT/US2022/077120 WO2023056264A1 (en) | 2021-09-29 | 2022-09-27 | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003948A true MX2024003948A (es) | 2024-06-28 |
Family
ID=84329267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003948A MX2024003948A (es) | 2021-09-29 | 2022-09-27 | Nuevos compuestos de sulfonilurea sustituidos como inhibidores de la actividad de interleucina-1. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240400561A1 (enExample) |
| EP (1) | EP4408843A1 (enExample) |
| JP (1) | JP2024538602A (enExample) |
| KR (1) | KR20240089127A (enExample) |
| CN (1) | CN118251393A (enExample) |
| AU (1) | AU2022356377A1 (enExample) |
| CA (1) | CA3233673A1 (enExample) |
| IL (1) | IL311784A (enExample) |
| MX (1) | MX2024003948A (enExample) |
| WO (1) | WO2023056264A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024538602A (ja) * | 2021-09-29 | 2024-10-23 | ビバ スター バイオサイエンシズ （スージョウ） カンパニー リミテッド | インターロイキン－１活性の阻害剤としての新規の置換スルホニル尿素化合物 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110914256A (zh) * | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| EP3649112A1 (en) * | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| TW201910317A (zh) * | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| MX2020001776A (es) * | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| TW201910314A (zh) * | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| CN111315733A (zh) * | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| GB201902327D0 (en) * | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| JP2024538602A (ja) * | 2021-09-29 | 2024-10-23 | ビバ スター バイオサイエンシズ （スージョウ） カンパニー リミテッド | インターロイキン－１活性の阻害剤としての新規の置換スルホニル尿素化合物 |
-
2022
- 2022-09-27 JP JP2024519269A patent/JP2024538602A/ja active Pending
- 2022-09-27 MX MX2024003948A patent/MX2024003948A/es unknown
- 2022-09-27 EP EP22801649.9A patent/EP4408843A1/en active Pending
- 2022-09-27 KR KR1020247014041A patent/KR20240089127A/ko active Pending
- 2022-09-27 AU AU2022356377A patent/AU2022356377A1/en active Pending
- 2022-09-27 CA CA3233673A patent/CA3233673A1/en active Pending
- 2022-09-27 US US18/696,901 patent/US20240400561A1/en active Pending
- 2022-09-27 CN CN202280075492.3A patent/CN118251393A/zh active Pending
- 2022-09-27 IL IL311784A patent/IL311784A/en unknown
- 2022-09-27 WO PCT/US2022/077120 patent/WO2023056264A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240089127A (ko) | 2024-06-20 |
| CA3233673A1 (en) | 2023-04-06 |
| JP2024538602A (ja) | 2024-10-23 |
| US20240400561A1 (en) | 2024-12-05 |
| EP4408843A1 (en) | 2024-08-07 |
| AU2022356377A1 (en) | 2024-04-11 |
| IL311784A (en) | 2024-05-01 |
| CN118251393A (zh) | 2024-06-25 |
| WO2023056264A1 (en) | 2023-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501611A1 (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| MX394961B (es) | Composiciones para usarse en el tratamiento de enfermedades relacionadas con la interleucina 6 | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2020006399A (es) | Derivados de sulfonil urea. | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2023009685A (es) | Inhibidores de tyk2 y sus usos. | |
| BRPI0508561A (pt) | 3-'4-heterociclil-1,2,3-triazol-1-il-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crÈnicas | |
| MX2022000961A (es) | Inhibidores triciclicos de kars dependientes de akr1c3. | |
| CO2023013469A2 (es) | Derivados de fósforo como nuevos inhibidores de sos1 | |
| WO2022175746A8 (en) | Tyk2 inhibitors and uses thereof | |
| EP4252755A3 (en) | Therapeutic compounds | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| PH12022550843A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| BR112019006113A2 (pt) | métodos de tratamento de distúrbios mitocondriais e metabólicos | |
| ZA202300912B (en) | Tyk-2 inhibitor | |
| MX2021003643A (es) | Derivados de terpenoides y usos de los mismos. | |
| MX2022004806A (es) | Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763). | |
| MX2025000151A (es) | Agonistas de trpml1 con oxazol y usos de los mismos | |
| WO2024099364A3 (en) | Fused multicyclic compounds and their use as parp1 inhibitors | |
| PH12022550846A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| GEAP202416390A (en) | Bicyclic heteroaromatic inhibitors of klk5 | |
| WO2020068950A8 (en) | Hdac1,2 inhibitors | |
| GEAP202516217A (en) | Compounds and compositions as sppl2a inhibitors |